Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental disorders that are characterized by deficits in social interaction, verbal and nonverbal communication, and restrictive interests and repetitive behaviors. While human genetic studies have revealed marked heritability in ASD, it has been challenging to translate this genetic risk into a biological mechanism that influences brain development relevant to the disorder phenotypes. This is partly due to the complex genetic architecture of ASD, which involves de novo gene mutations, genomic abnormalities, and common genetic variants. Rather than trying to reconstitute the clinical disorder, using genetic model animals to examine specific features of core ASD pathophysiology offers unique opportunities for refining our understanding of neurodevelopmental mechanisms in ASD. A variety of ASD-relevant phenotypes can now be investigated in rodents, including stereotyped and repetitive behaviors, and deficits in social interaction and communication. In this review, we focus on several prevailing mouse models and discuss how studies have advanced our understanding of synaptic mechanisms that may underlie ASD pathophysiology. Although synaptic perturbations are not the only alterations relevant for ASD, we reason that understanding the synaptic underpinnings of ASD using mouse models may provide mechanistic insights into its etiology and lead to novel therapeutic and interventional strategies.

Keywords:
Autism, Genetic mutation, Mouse, Synaptic dysfunction, Neural development, Copy number variation, Chromosomal abnormality
1.
Kogan MD, et al: Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009;124:1395–1403.
2.
Geschwind DH, Levitt P: Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 2007;17:103–111.
3.
Abrahams BS, Geschwind DH: Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008;9:341–355.
4.
Walsh CA, Morrow EM, Rubenstein JL: Autism and brain development. Cell 2008;135:396–400.
5.
Scherer SW, Dawson G: Risk factors for autism: translating genomic discoveries into diagnostics. Hum Genet 2011;130:123–148.
6.
Levitt P, Campbell DB: The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest 2009;119:747–754.
7.
Moy SS, Nadler JJ: Advances in behavioral genetics: mouse models of autism. Mol Psychiatry 2008;13:4–26.
8.
Schaaf CP, Zoghbi HY: Solving the autism puzzle a few pieces at a time. Neuron 2011;70:806–808.
9.
Huttenlocher PR, Dabholkar AS: Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol 1997;387:167–178.
10.
Casanova MF, et al: A topographic study of minicolumnar core width by lamina comparison between autistic subjects and controls: possible minicolumnar disruption due to an anatomical element in-common to multiple laminae. Brain Pathol 2010;20:451–458.
11.
Hutsler JJ, Zhang H: Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res 2010;1309:83–94.
12.
Irwin SA, et al: Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 2001;98:161–167.
13.
Pfeiffer BE, Huber KM: Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J Neurosci 2007;27:3120–3130.
14.
Zoghbi HY: Postnatal neurodevelopmental disorders: meeting at the synapse? Science 2003;302:826–830.
15.
State MW: The genetics of child psychiatric disorders: focus on autism and Tourette syndrome. Neuron 2010;68:254–269.
16.
Thompson BL, Levitt P: The clinical-basic interface in defining pathogenesis in disorders of neurodevelopmental origin. Neuron 2010;67:702–712.
17.
Persico AM, Bourgeron T: Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006;29:349–358.
18.
Silverman JL, et al: Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci 2010;11:490–502.
19.
Aldinger KA, et al: SnapShot: genetics of autism. Neuron 2011;72:418–418 e1.
20.
Insel TR: The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010;65:768–779.
21.
El-Fishawy P, State MW: The genetics of autism: key issues, recent findings, and clinical implications. Psychiatr Clin North Am 2010;33:83–105.
22.
State MW, Levitt P: The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 2011;14:1499–1506.
23.
Toro R, et al: Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet 2010;26:363–372.
24.
Coba MP, et al: Neurotransmitters drive combinatorial multistate postsynaptic density networks. Sci Signal 2009;2:ra19.
25.
Betancur C, Sakurai T, Buxbaum JD: The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009;32:402–412.
26.
Dalva MB, McClelland AC, Kayser MS: Cell adhesion molecules: signalling functions at the synapse. Nat Rev Neurosci 2007;8:206–220.
27.
Williams ME, de Wit J, Ghosh A: Molecular mechanisms of synaptic specificity in developing neural circuits. Neuron 2010;68:9–18.
28.
Sudhof TC: Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008;455:903–911.
29.
Feng J, et al: High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci Lett 2006;409:10–13.
30.
Szatmari P, et al: Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007;39:319–328.
31.
Zahir FR, et al: A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha. J Med Genet 2008;45:239–243.
32.
Xu LM, et al: AutismKB: an evidence-based knowledgebase of autism genetics. Nucleic Acids Res, E-pub ahead of print.
33.
Kattenstroth G, et al: Postsynaptic N-methyl-d-aspartate receptor function requires alpha-neurexins. Proc Natl Acad Sci USA 2004;101:2607–2612.
34.
Lisman J, Raghavachari S: A unified model of the presynaptic and postsynaptic changes during LTP at CA1 synapses. Sci STKE 2006;2006:re11.
35.
Nicoll RA, Malenka RC: Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann NY Acad Sci 1999;868:515–525.
36.
Zhang C, et al: Neurexins physically and functionally interact with GABA(A) receptors. Neuron 2010;66:403–416.
37.
Etherton MR, et al: Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci USA 2009;106:17998–18003.
38.
Jamain S, et al: Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003;34:27–29.
39.
Laumonnier F, et al: X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004;74:552–557.
40.
Yan J, et al: Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol Psychiatry 2005;10:329–332.
41.
Tabuchi K, et al: A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science 2007;318:71–76.
42.
Levitt P, Eagleson KL, Powell EM: Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci 2004;27:400–406.
43.
Rubenstein JL, Merzenich MM: Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003;2:255–267.
44.
Jamain S, et al: Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci USA 2008;105:1710–1715.
45.
Hayashi MK, et al: The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell 2009;137:159–171.
46.
Bonaglia MC, et al: Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet 2006;43:822–828.
47.
Durand CM, et al: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007;39:25–27.
48.
Roussignol G, et al: Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 2005;25:3560–3570.
49.
Cusmano-Ozog K, Manning MA, Hoyme HE: 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. Am J Med Genet C Semin Med Genet 2007;145C:393–398.
50.
Durand CM, et al: SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 2012;17:71–84.
51.
Wang X, et al: Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 2011;20:3093–3108.
52.
Peca J, et al: Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011;472:437–442.
53.
Bangash MA, et al: Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 2011;145:758–772.
54.
Penagarikano O, et al: Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 2011;147:235–246.
55.
Poliak S, et al: Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron 1999;24:1037–1047.
56.
Sharma S, et al: Genome-wide association studies of adolescent idiopathic scoliosis suggest candidate susceptibility genes. Hum Mol Genet 2011;20:1456–1466.
57.
Strauss KA, et al: Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006;354:1370–1377.
58.
Alarcon M, et al: Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 2008;82:150–159.
59.
Arking DE, et al: A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet 2008;82:160–164.
60.
Bakkaloglu B, et al: Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet 2008;82:165–173.
61.
Stein MB, et al: A common genetic variant in the neurexin superfamily member CNTNAP2 is associated with increased risk for selective mutism and social anxiety-related traits. Biol Psychiatry 2011;69:825–831.
62.
Vernes SC, et al: A functional genetic link between distinct developmental language disorders. N Engl J Med 2008;359:2337–2345.
63.
Scott-Van Zeeland AA, et al: Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2. Sci Transl Med 2010;2:56–80.
64.
Poliak S, et al: Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 2003;162:1149–1160.
65.
Schmidt C, et al: Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699–702.
66.
Uehara Y, et al: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702–705.
67.
Mukamel Z, et al: Regulation of MET by FOXP2, genes implicated in higher cognitive dysfunction and autism risk. J Neurosci 2011;31:11437–11442.
68.
Judson MC, Amaral DG, Levitt P: Conserved subcortical and divergent cortical expression of proteins encoded by orthologs of the autism risk gene MET. Cereb Cortex 2011;21:1613–1626.
69.
Judson MC, et al: Dynamic gene and protein expression patterns of the autism-associated met receptor tyrosine kinase in the developing mouse forebrain. J Comp Neurol 2009;513:511–531.
70.
Campbell DB, et al: Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 2008;1:159–168.
71.
Campbell DB, et al: A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006;103:16834–16839.
72.
Marshall CR, et al: Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008;82:477–488.
73.
Sousa I, et al: MET and autism susceptibility: family and case-control studies. Eur J Hum Genet 2009;17:749–758.
74.
Jackson PB, et al: Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res 2009;2:232–236.
75.
Thanseem I, et al: Further evidence for the role of MET in autism susceptibility. Neurosci Res 2010;68:137–141.
76.
Campbell DB, et al: Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol 2007;62:243–250.
77.
Voineagu I: Gene expression studies in autism: Moving from the genome to the transcriptome and beyond. Neurobiol Dis 2012;45:69–75.
78.
Judson MC, Eagleson KL, Levitt P: A new synaptic player leading to autism risk: Met receptor tyrosine kinase. J Neurodev Disord 2011;3:282–292.
79.
Powell EM, Mars WM, Levitt P: Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron 2001;30:79–89.
80.
Eagleson KL, et al: The autism risk genes MET and PLAUR differentially impact cortical development. Autism Res 2011;4:68–83.
81.
Eagleson KL, Bonnin A, Levitt P: Region- and age-specific deficits in gamma-aminobutyric acidergic neuron development in the telencephalon of the uPAR(–/–) mouse. J Comp Neurol 2005;489:449–466.
82.
Powell EM, et al: Differential regulation of thalamic and cortical axonal growth by hepatocyte growth factor/scatter factor. Dev Neurosci 2003;25:197–206.
83.
Judson MC, et al: Evidence of cell-nonautonomous changes in dendrite and dendritic spine morphology in the met-signaling-deficient mouse forebrain. J Comp Neurol 2010;518:4463–4478.
84.
Matsuzaki M, et al: Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci 2001;4:1086–1092.
85.
Qiu S, et al: Circuit-specific intracortical hyperconnectivity in mice with deletion of the autism-associated Met receptor tyrosine kinase. J Neurosci 2011;31:5855–5864.
86.
Gatchel JR, Zoghbi HY: Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005;6:743–755.
87.
Orr HT, Zoghbi HY: Trinucleotide repeat disorders. Annu Rev Neurosci 2007;30:575–621.
88.
Dahlhaus R, El-Husseini A: Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res 2010;208:96–105.
89.
Consortium T: Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell 1994;78:23–33.
90.
Verkerk AJ, et al: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905–914.
91.
Bernardet M, Crusio WE: Fmr1 KO mice as a possible model of autistic features. Scientific World Journal 2006;6:1164–1176.
92.
Peier AM, et al: (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 2000;9:1145–1159.
93.
Comery TA, et al: Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA 1997;94:5401–5404.
94.
Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27:370–377.
95.
Dolen G, et al: Correction of fragile X syndrome in mice. Neuron 2007;56:955–962.
96.
Hays SA, Huber KM, Gibson JR: Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. J Neurosci 2011;31:14223–14234.
97.
Berry-Kravis E, Knox A, Hervey C: Targeted treatments for fragile X syndrome. J Neurodev Disord 2011;3:193–210.
98.
Krueger DD, Bear MF: Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 2011;62:411–429.
99.
Huber KM, et al: Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002;99:7746–7750.
100.
Desai NS, et al: Early postnatal plasticity in neocortex of Fmr1 knockout mice. J Neurophysiol 2006;96:1734–1745.
101.
Larson J, et al: Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J Neurosci 2005;25:9460–9469.
102.
Li J, et al: Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002;19:138–151.
103.
Olmos-Serrano JL, et al: Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 2010;30:9929–9938.
104.
Bureau I, Shepherd GM, Svoboda K: Circuit and plasticity defects in the developing somatosensory cortex of FMR1 knock-out mice. J Neurosci 2008;28:5178–5188.
105.
Amir RE, et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185–188.
106.
Moretti P, Zoghbi HY: MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev 2006;16:276–281.
107.
Casanova MF, et al: Rett syndrome as a minicolumnopathy. Clin Neuropathol 2003;22:163–168.
108.
Belichenko PV, et al: Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 1994;5:1509–1513.
109.
Kaufmann WE, Moser HW: Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 2000;10:981–991.
110.
Chahrour M, Zoghbi HY: The story of Rett syndrome: from clinic to neurobiology. Neuron 2007;56:422–437.
111.
Guy J, et al: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001;27:322–326.
112.
Samaco RC, et al: A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet 2008;17:1718–1727.
113.
Zhou Z, et al: Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006;52:255–269.
114.
Cohen S, et al: Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 2011;72:72–85.
115.
Wood L, et al: Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency. J Neurosci 2009;29:12440–12448.
116.
Chao HT, et al: Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010;468:263–269.
117.
Ballas N, et al: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 2009;12:311–317.
118.
Estivil X, Armengol L: Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet 2007;3:1787–1799.
119.
Merikangas AK, Corvin AP, Gallagher L: Copy-number variants in neurodevelopmental disorders: promises and challenges. Trends Genet 2009;25:536–544.
120.
Sanders SJ, et al: Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011;70:863–885.
121.
Levy D, et al: Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 2011;70:886–897.
122.
Sebat J, et al: Strong association of de novo copy number mutations with autism. Science 2007;316:445–449.
123.
Gilman SR, et al: Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011;70:898–907.
124.
Pinto D, et al: Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010;466:368–372.
125.
van der Weyden L, Bradley A: Mouse chromosome engineering for modeling human disease. Annu Rev Genomics Hum Genet 2006;7:247–276.
126.
Glessner JT, et al: Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009;459:569–573.
127.
Hogart A, et al: The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. Neurobiol Dis 2010;38:181–191.
128.
Nicholls RD, Knepper JL: Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001;2:153–175.
129.
Nakatani J, et al: Abnormal behavior in a chromosome-engineered mouse model for human 15q11–13 duplication seen in autism. Cell 2009;137:1235–1246.
130.
Seeburg PH: A-to-I editing: new and old sites, functions and speculations. Neuron 2002;35:17–20.
131.
Kumar RA, et al: Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet 2008;17:628–638.
132.
Weiss LA, et al: Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008;358:667–675.
133.
Jacquemont S, et al: Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature 2011;478:97–102.
134.
McCarthy SE, et al: Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009;41:1223–1227.
135.
Horev G, et al: Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism. Proc Natl Acad Sci USA 2011;108:17076–17081.
136.
Bijlsma EK, et al: Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet 2009;52:77–87.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.